| INTRODUCTION
Sickle Cell Anemia (SCA) is one of the most life threatening conditions in the world. 1 About 2.3% of world population is affected and the Democratic Republic of Congo (DRC) is the third most affected country worldwide with an estimated incidence of 40 000 newborns per year. 2, 3 Clinical features mainly encompass deadly anemia, painful vaso-occlusive crises and increased susceptibility to infections. 4 However, the severity of these features varies from one patient to another and from one haplotype to another. 5 The Bantu haplotype, predominant in the Central Africa, presents the most severe clinical expression of the Sickle Cell Disease. 6 A strong correlation has been established between the clinical severity and the level of fetal hemoglobin. 5, 7, 8 Classically, the expression of HBG1 (142200) and HBG2
(14250)genes, critical for the synthesis of fetal hemoglobin (HbF), is dramatically reduced shortly before birth and remains as such after birth. 7 The residual amount of HbF in adults is usually less than 1% of total hemoglobin. 9 Interestingly, in rare individuals, the level of HbF may remain significantly elevated. It is known that an HbF level greater than or equal to 15% is required to inhibit HbS polymerization. This asymptomatic hereditary anomaly is defined as Hereditary Persistence of Fetal Hemoglobin (HPFH). 9 Fortunately, the HPFH(141900) was
shown to be beneficial to individuals with sickle cell disease. The elevated HbF levels interfere with the polymerization induced by S hemoglobin (HbS) and reduce the Mean Corpuscular HbS concentration. 10 By doing so, HPFH(141900) improves the clinical condition for SCA patients. Because of this modulating effect in SCA, multiple studies have been conducted to uncover the underlying mechanism for the inter-individual variability in HbF values. So far, several quantitative trait loci (QTL) cis and trans to hemoglobin genes have shown significant association with high levels of HbF. 11, 12 The BCL11A on chromosome 2p and HBSL1-MYB intergenic region HMIP on 6q23 are among the most interesting modifiers loci. 10, 13 BCL11A is known to be a repressor of the transcription of the γ-globin gene. In addition to two SNP haplotypes in the enhancer elements, the second intron of BCL11A contains 3 DNase hypersensitive sites (DHS), respectively, located at+62, +58 and +55 kb from the transcription initiation site. 14 These sites are important for the regulation of BCL11A expression by erythroid-specific enhancers. For its part, C-myb plays a crucial role in the control of the balance of erythroid differentiation and cell proliferation, and regulates the levels of HbF by an unknown mechanism. 
| METHODS

| Subjects, study design and case definitions
This cross-sectional study was conducted in the Sickle cell Centre of Yolo (Kinshasa, DRC). This is the largest and the reference health facility devoted to care for SCA patients in the DRC. During the outpatient clinics, patients were recruited based on the fact that they have SCA, were free of pain and were not transfused within the preceding 100 days as previously suggested. 15 We defined HPFH(141900) as fetal hemoglobin value higher than 1%. Patients with HPFH(141900) were assigned to group 1 whereas those without HPFH were allocated to group 2. A total of 102 SCA patients in steady state were recruited including 66 in the group 1 and 36 in the group 2. All patients were homozygous for the β-globin gene mutation. The mean age of the recruited patients was 23.5±13.7 years. Five ml of peripheral venous blood on EDTA was drawn from each participant.
| Laboratory testing
We performed a standard screening for SCA at the Institut National Genomic DNA was extracted locally at the INRB using the standard "salting out" method as previously described. 24 DNA samples were later normalized to 50 ηg/μL with a Dropsense ® robot (Trinean)
at the Center for Human Genetics, KU Leuven, Belgium. At least 12 SNPs are known to be associated to HPFH(141900).
Interestingly, eight of these have been studied in populations genetically close to the Congolese, namely Afro-Brazilians, African-American and West-African. 11, 16, 25 Therefore, we included these eight in our SNP panel which contained 4 SNPs in the BCL11A gene (rs11886868, rs766432, rs7606173, rs6706648) and four others on the HBS1L-MYB intergenic region (rs7776054, rs9399137, rs4895441, rs4895440).
Information on primers and PCR product are given in the Table 1 . 
| Statistical analyses
Results were manually entered into a microcomputer and analyzed using the Excel Version 2002 (CDC) and they were exported on SPSS On the other hand, (calculated X 2 more than 3.84), H0 was rejected and it was concluded that the population does not follow the Hardy
Weinberg principle with an α risk=5%, to be wrong. The observed frequencies of genotypes between the two groups were compared with the Fisher test. A P value<.05 was considered significant.
| Ethical considerations
The study protocol was reviewed and approved by the Internal Review Board of the University of Kinshasa, under the number ESP/ CE/027B/2011. Aims and procedures of the study were explained to the participants and we provided answers when they had questions.
They were informed about their right to withdraw at any time without further obligation. Privacy was guaranteed to participants. All major participants provided written consent for study participation. Since some participants were minors, their legal representatives provided signed consent for study participation.
| RESULTS
The HbF level ranged from 4.6% to 33.3% (mean 13.74±6.32%) in the G1. 
| Variants of the BCL11A gene
The 
| Variants of the HBS1L-MYB intergenic region
| Relation between minor allele frequencies
The observed MAFs of the BCL11A variants were lower in G1 compared to G2 with a significant difference recorded for the allele T at rs6706648 (Table 5 ).
| DISCUSSION
In the present report, 8 SNPs at 2 QTL involve in the variability of HbF expression were assessed in 102 Congolese SCA patients. This is the first study of its kind in the Central African region. At each SNP, we counted allele frequency and computed expected genotypes based on Hardy-Weinberg Laws (HWL). We also analyzed the distribution of genotypes at these eight polymorphic positions between patients with HPFH(141900) (Group 1) and SCA patients without HPFH(141900) (Group 2).
Our study showed that the values of WBCs, reticulocytes, platelets, CRP, and LDH were higher in group 2 of patients without The consequence is the moderation of the clinical form of the disease, which is reflect by the low levels of these hematologic parameters in group 1 as reported in previous studies worldwide. 13, 26 A homogeneous distribution with Hardy-Weinberg equilibrium, of the rs11886868 (BCL11A) in the G1 group (Hb SS-HbF) was For the four BCL11A polymorphisms, the allele C at rs11886868 (BCL11A) was present only in patients with increased fetal hemoglobin (G1). Also, genotype frequencies for rs11886868 showed significant difference between both groups with regard to the HWL (Table 3 ).
In HBSL1-MYB intergenic region, a homogeneous distribution of the rs9399137 (HBS1L-MYB) was observed with the balance of LHW, Independently, G1 presented skewed HWL for rs9399137 whereas G2 deviated from expected genotype counts for rs4895440, although the difference between the two groups was not significant.
These data show that some alleles and genotypes are not randomly distributed between the two groups but are significantly enriched among patients with persistent fetal hemoglobin (Tables 3   and 4 ). This enforcement of HWL presumably suggests a correlation between the skewed distribution of these SNPs and the distribution of fetal hemoglobin among our patients. Significant associations between rs11886868(BCL11A) and rs9300137(HBS1L-MYB) the fetal hemoglobin were previously established with a variance effect 11.8%
for rs11886868. 11, 12, 23, 26, 27 The association rs11886868 (BCL11A) and rs 9300137 (HBS1L-MYB) with HPFH (141900) has also been reported by other authors in the Sub-Saharan African population. 21, [24] [25] [26] [27] [28] [29] [30] During the analysis, we noticed that among G1 patients, carriers of the allele C at rs9399137 always carried the allele G at rs7776054
and this G-C haplotype was not found among G2 patients (Table 4) . 
T A B L E 4 Frequencies of the genotypes of the variants of the HBSL1-MYB intergenic region
T A B L E 5 Relation between minor allele frequencies
There is possibly a preferential and simultaneous enrichment of the two SNPs. Previously, Uda et al., pointed out that the rs11886868 (BCL11A) was in Linkage Disequilibrium (LD) with some neighboring SNPs. 12 Moreover, it is widely known that the African population is the most ancient one, with highest recombination rate and smallest haplotype blocks. We can anticipate that the 2 HBS1L-MYB SNPs may belong to a block and be associated to HPFH(141900). However, the current study did not target haplotypes. Further studies are needed to deeply investigate this assumption.
We did not encounter certain alleles in our cohort since certain SNPs such as rs7776054 and rs4895441 were homozygous in all patients. This could probably reflect the allele distribution in the general Congolese population.
As a pioneer and preliminary study, our research suggests that alleles at some of studied SNPs are not equally distributed among patients with HPFH (141900) and those without. Thus, this points to a likely association between these polymorphisms and HPFH (141900) in the Congolese population. However, larger studies are needed in order to provide stronger evidence and draw a definite conclusion.
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